Unnamed: 0,title,date,stock,sentiment
883756.0,Navidea Biopharmaceuticals Announces Acceptance Of Abstract For Presentation At The European League Against Rheumatism (EULAR) Congress,2020-06-03 07:33:00-04:00,NAVB,positive
883757.0,28 Stocks Moving in Tuesday's Pre-Market Session,2020-05-26 07:18:00-04:00,NAVB,neutral
883758.0,71 Biggest Movers From Friday,2020-05-26 04:30:00-04:00,NAVB,neutral
883759.0,Mid-Afternoon Market Update: NASDAQ Turns Higher; Hewlett Packard Shares Tumble,2020-05-22 14:47:00-04:00,NAVB,positive
883760.0,"HC Wainwright & Co. Maintains Buy on Navidea Biopharmaceutical, Raises Price Target to $6",2020-05-22 12:54:00-04:00,NAVB,neutral
883761.0,46 Stocks Moving In Friday's Mid-Day Session,2020-05-22 12:45:00-04:00,NAVB,neutral
883762.0,Mid-Day Market Update: LiveRamp Surges Following Q4 Results; Syndax Pharmaceuticals Shares Plummet,2020-05-22 12:39:00-04:00,NAVB,positive
883763.0,"H.C. Wainwright Reiterates Buy On Navidea Biopharmaceuticals, Raises Price Target From $4 To $6; Says 'Interim results further support tilmanocept's potential for use in RA quantitative imaging. '",2020-05-22 12:24:00-04:00,NAVB,positive
883764.0,Mid-Morning Market Update: Markets Fall; Alibaba Earnings Beat Estimates,2020-05-22 10:12:00-04:00,NAVB,neutral
883765.0,30 Stocks Moving in Friday's Pre-Market Session,2020-05-22 07:18:00-04:00,NAVB,neutral
883766.0,"The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray",2020-05-22 07:10:00-04:00,NAVB,neutral
883767.0,Navidea Biopharmaceuticals Announces Results Of Second Interim Analysis Of Ongoing Phase 2B Study In Rheumatoid Arthritis,2020-05-21 16:30:00-04:00,NAVB,neutral
883768.0,"Navidea Biopharmaceutical Q1 EPS $(0.130) Up From $(0.240) YoY, Sales $156.272K Up From $136.032K YoY",2020-05-14 16:02:00-04:00,NAVB,neutral
883769.0,"The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger",2020-05-14 08:32:00-04:00,NAVB,positive
883770.0,Navidea Biopharmaceuticals Regains Commercialization And Distributions Rights In Europe For LYMPHOSEEK,2020-05-11 07:52:00-04:00,NAVB,neutral
883771.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,NAVB,neutral
883772.0,Navidea Biopharmaceuticals Signs Letter Of Intent With WorldCare Clinical To Partner On Navidea's Rheumatoid Arthritis Clinical Imaging Workflow And Commercialization,2020-03-31 07:36:00-04:00,NAVB,neutral
883773.0,"Navidea Biopharma Reports Issuance Of Patent Extension For Lymphoseek For Added 5 Years Through May 12, 2025",2020-03-20 07:01:00-04:00,NAVB,neutral
883774.0,"Navidea Biopharmaceutical Q4 EPS $(0.15) Misses $(0.12) Estimate, Sales $119.299K Down From $119.321K YoY",2020-03-11 16:06:00-04:00,NAVB,negative
883775.0,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment",2020-03-11 08:03:00-04:00,NAVB,positive
883776.0,"The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues",2020-03-08 16:14:00-04:00,NAVB,negative
883777.0,"H.C. Wainwright Reiterates Buy on Navidea Biopharmaceutical, Raises Price Target to $4",2020-03-02 07:22:00-05:00,NAVB,neutral
883778.0,Navidea Biopharma Reports Regained NYSE American Compliance,2020-02-14 11:58:00-05:00,NAVB,neutral
883779.0,Navidea Biopharma Shares Halted,2020-02-14 11:52:00-05:00,NAVB,positive
883780.0,"Navidea Biopharma Reports $4.2M Sale Of Ohio Court Judgment, $3.4M Equity Raise For $7.6M In Added Funding",2020-02-14 07:31:00-05:00,NAVB,neutral
883781.0,Navidea Biopharmaceuticals Obtains Partial Dismissal of Claims in New York,2019-12-30 17:19:00-05:00,NAVB,neutral
883782.0,"Navidea Biopharmaceuticals Shares Resume Trade, Up 33% at $1.18",2019-12-02 14:34:00-05:00,NAVB,positive
883783.0,Navidea Biopharmaceuticals Wins Summary Judgment in Ohio,2019-12-02 14:09:00-05:00,NAVB,positive
883784.0,"Navidea Biopharmaceuticals Shares Halted, News Pending",2019-12-02 11:17:00-05:00,NAVB,positive
883785.0,"H.C. Wainwright Initiates Coverage On Navidea Biopharmaceutical with Buy Rating, Announces $3 Price Target",2019-11-22 08:08:00-05:00,NAVB,neutral
883786.0,Navidea Biopharmaceutical Q3 Sales $236.811K Up From $231.458K YoY,2019-11-07 17:13:00-05:00,NAVB,neutral
883787.0,Navidea Biopharmaceuticals Earlier Announced Announce Preclinical Therapeutic Research Collaboration With IMV Inc. To Explore Potential Combinatory Effect With Their Platform-Based Immunotherapies,2019-11-07 09:29:00-05:00,NAVB,neutral
883788.0,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs",2019-11-07 07:18:00-05:00,NAVB,negative
883789.0,"Navidea Biopharma Reports Results From First Interim Analysis Of Ongoing Phase 2B Study In RA: Showed Quantitative Repeatability, Stability Of Signal",2019-10-29 07:36:00-04:00,NAVB,neutral
883790.0,"Navidea Biopharmaceutical Q2 EPS $(0.24) Down From $(0.02) YoY, Sales $206K May Not Compare To $542.127K YoY",2019-08-08 16:20:00-04:00,NAVB,neutral
883791.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Friday, July 12, 2019",2019-07-12 10:03:00-04:00,NAVB,positive
883792.0,55 Biggest Movers From Yesterday,2019-07-12 05:18:00-04:00,NAVB,neutral
883793.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Radar Tool For Thu., July 11, 2019",2019-07-11 13:21:00-04:00,NAVB,positive
883794.0,48 Stocks Moving In Thursday's Mid-Day Session,2019-07-11 12:50:00-04:00,NAVB,neutral
883795.0,What Caused The Opening Gap In Navidea Biopharmaceuticals?,2019-07-11 10:01:00-04:00,NAVB,neutral
883796.0,Navidea Biopharmaceuticals shares are trading higher after Maxim Group initiated coverage on the stock with a Buy rating.,2019-07-11 09:14:00-04:00,NAVB,positive
883797.0,Navidea Biopharma Shares Up 68% Premarket; Hearing Maxim Set $2 Price Target On Stock,2019-07-11 08:38:00-04:00,NAVB,positive
883798.0,Maxim Group Initiates Coverage On Navidea Biopharmaceutical with Buy Rating,2019-07-11 08:35:00-04:00,NAVB,neutral
883799.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs",2019-06-22 15:07:00-04:00,NAVB,neutral
883800.0,46 Biggest Movers From Friday,2019-06-17 06:25:00-04:00,NAVB,neutral
883801.0,Mid-Afternoon Market Update: Dow Turns Positive; India Globalization Capital Shares Spike Higher,2019-06-14 15:15:00-04:00,NAVB,positive
883802.0,35 Stocks Moving In Friday's Mid-Day Session,2019-06-14 12:11:00-04:00,NAVB,neutral
883803.0,Mid-Day Market Update: Renren Drops After Q1 Results; ArQule Shares Surge,2019-06-14 12:10:00-04:00,NAVB,positive
883804.0,"The Daily Biotech Pulse:  Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA",2019-06-14 08:47:00-04:00,NAVB,neutral
883805.0,Navidea Biopharmaceuticals shares are trading lower after the company announced a common stock offering of 8 million shares at $0.75 per share.,2019-06-14 08:21:00-04:00,NAVB,positive
883806.0,26 Stocks Moving In Friday's Pre-Market Session,2019-06-14 08:01:00-04:00,NAVB,neutral
883807.0,Navidea Biopharmaceuticals Prices 8M Share Public Offering of Common Stock @$0.75/Share,2019-06-14 04:13:00-04:00,NAVB,positive
883808.0,Navidea Biopharmaceuticals Reports Common Stock Offering; Size Not Disclosed,2019-06-13 17:31:00-04:00,NAVB,neutral
883809.0,Navidea Biopharmaceuticals shares are trading higher after the company regained direct control of Intellectual Property.,2019-06-13 16:34:00-04:00,NAVB,positive
883810.0,Navidea Biopharmaceuticals Regains Direct Control Of Intellectual Property,2019-06-13 16:24:00-04:00,NAVB,positive
883811.0,"The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes",2019-06-13 07:44:00-04:00,NAVB,negative
883812.0,"The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix",2019-06-07 07:24:00-04:00,NAVB,positive
883813.0,"Navidea Biopharmaceutical Q1 EPS $(0.24) Up From $(0.83) YoY, Sales $136.032K Down From $276.445K YoY",2019-05-08 17:00:00-04:00,NAVB,neutral
883814.0,48 Biggest Movers From Friday,2019-04-29 05:43:00-04:00,NAVB,neutral
883815.0,"Navidea Biopharmaceuticals Announces Comparative Study to Evaluate The Potential Utility of Tilmanocept In Patients with Tuberculosis (""TB"")",2019-04-26 07:32:00-04:00,NAVB,neutral
883816.0,50 Biggest Movers From Yesterday,2019-04-09 06:48:00-04:00,NAVB,neutral
883817.0,"Navidea Biopharma 8-K Shows Co. Received NYSE American Notice Related To Non Compliance With $2M Minimum Shareholder Equity Requirement; Co. Has Until Apr. 15, 2019 To Be Considered For Continued Trading",2019-04-08 17:38:00-04:00,NAVB,neutral
883818.0,Mid-Afternoon Market Update: Art's-Way Manufacturing Drops After Q1 Results; Navidea Biopharmaceuticals Shares Climb,2019-04-08 14:47:00-04:00,NAVB,positive
883819.0,Mid-Day Market Update: Crude Oil Up 1.7%; BP Prudhoe Bay Royalty Trust Shares Plunge,2019-04-08 13:06:00-04:00,NAVB,positive
883820.0,48 Stocks Moving In Monday's Mid-Day Session,2019-04-08 12:48:00-04:00,NAVB,neutral
883821.0,Navidea Biopharmaceuticals shares are trading higher after the company reported it received FDA feedback related to its Rheumatoid Arthritis trial for Phase 2B and the FDA said it would continue to work with the company for Phase 3 Trial.,2019-04-08 08:39:00-04:00,NAVB,positive
883822.0,"UPDATE: Navidea Says Is Prepared To Initiate Phase 3 Study, NAV3-31",2019-04-08 07:33:00-04:00,NAVB,positive
883823.0,"Navidea Biopharma Reports Received FDA Feedback Related to Rheumatoid Arthritis Trial Design: FDA Said First Study, Phase 2b Trial, Is Aligned With Expectations For Studies, Will Continue To Work With Co. For Phase 3 Trial",2019-04-08 07:33:00-04:00,NAVB,neutral
883824.0,Navidea Biopharma Reports Will Present Results Of NAV3-21 Study At SNMMI Meeting In Jun. 2019,2019-04-02 16:10:00-04:00,NAVB,neutral
883825.0,Navidea Biopharmaceuticals shares are trading higher after the company announced a $3M stock purchase agreement with an existing investor.,2019-03-25 08:42:00-04:00,NAVB,positive
883826.0,Navidea Biopharma Reports $3M Private Placement,2019-03-22 17:09:00-04:00,NAVB,neutral
883827.0,"Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO",2019-03-07 07:48:00-05:00,NAVB,negative
883828.0,Patterson Companies Sees FY19 Adj. EPS $1.40-$1.45,2019-02-28 07:08:00-05:00,NAVB,neutral
883829.0,"Navidea Biopharma Reports Extension Of NYSE American Listing Until Mar. 31, 2019 To Regain Compliance",2019-02-01 07:02:00-05:00,NAVB,neutral
883830.0,Navidea Biopharma Announces the Ohio Supreme Court has Dismissed a Petition Filed by Capital Royalty Partners,2019-01-24 07:07:00-05:00,NAVB,positive
883831.0,"Navidea Biopharma Reports Patent Extension For Lymphoseek For Added 5 Yers To May 12, 2025",2018-12-07 06:56:00-05:00,NAVB,neutral
883832.0,"Navidea Biopharmaceutical Q3 EPS $(0.02) Down From $(0.01) YoY, Sales $231.458K Up From $223.669K YoY",2018-11-07 17:41:00-05:00,NAVB,neutral
883833.0,"Navidea Biopharma Shares Resume Trade, Now Up 4%",2018-11-02 10:50:00-04:00,NAVB,positive
883834.0,"UPDATE: Navidea Says Court Granted Motion To Dismiss, Directed Judgement In Favor Of Co.",2018-11-02 10:44:00-04:00,NAVB,positive
883835.0,"UPDATE: Navidea Says Court Disagreed With Platinum-Montaur Claim Of Unjust Enrichment On Similar Grounds, Found Firm 'lacked any sufficient personal stake to maintain claims against Navidea'",2018-11-02 10:44:00-04:00,NAVB,negative
883836.0,"UPDATE: Navidea Biopharma Filing Shows Court Rejected Platinum-Montaur Claim That Assignment Of Co. Note Was Partial Assignment, Found 'Assignment Agreement unambiguously assigned the entirety of Platinum-Montaur's interest in the Navidea debt to PPCO'",2018-11-02 10:43:00-04:00,NAVB,positive
883837.0,"Navidea Biopharma 8-K Shows Platinum-Montaur Asserted Its Assignment To PPCO Was Only A Partial Assignment, $1.5M Remained Due, Owing to Platinum-Montaur",2018-11-02 10:42:00-04:00,NAVB,neutral
883838.0,"Navidea Biopharmaceuticals Shares Halted, News Pending",2018-11-02 10:30:00-04:00,NAVB,positive
883839.0,Navidea Biopharmaceuticals Reportes Court Dismisses Claims Against Co. By Platinum-Montaur Life Sciences,2018-10-31 17:31:00-04:00,NAVB,neutral
883840.0,"Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American, Common Stock Will Continue To Be Listed",2018-10-30 16:46:00-04:00,NAVB,positive
883841.0,60 Biggest Movers From Yesterday,2018-09-19 05:08:00-04:00,NAVB,neutral
883842.0,44 Stocks Moving In Tuesday's Mid-Day Session,2018-09-18 12:46:00-04:00,NAVB,neutral
883843.0,Mid-Morning Market Update: Markets Open Higher; AutoZone Profit Tops Views,2018-09-18 10:34:00-04:00,NAVB,positive
883844.0,"The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares",2018-09-18 08:44:00-04:00,NAVB,positive
883845.0,22 Stocks Moving In Tuesday's Pre-Market Session,2018-09-18 08:00:00-04:00,NAVB,neutral
883846.0,Navidea Biopharmaceuticals shares are up 16.3% after the company reported acceptance into the National Institutes of Health Commercialization Accelerator Program.,2018-09-17 17:52:00-04:00,NAVB,positive
883847.0,Navidea Biopharma Reports Acceptance Into National Institutes Of Health Commercialization Accelerator Program,2018-09-17 17:30:00-04:00,NAVB,positive
883848.0,"Stocks Which Set New 52-Week Low Yesterday, August 16th",2018-08-17 10:40:00-04:00,NAVB,negative
883849.0,"Stocks Which Set New 52-Week Low Yesterday, August 15th",2018-08-16 11:15:00-04:00,NAVB,negative
883850.0,Navidea Biopharmaceuticals Receives Listing Noncompliance Notice from NYSE,2018-08-15 17:47:00-04:00,NAVB,neutral
883851.0,"Navidea Biopharmaceutical Q2 EPS $(0.02), Same YoY, Sales $542.127M Up From $611.599K YoY",2018-08-08 18:07:00-04:00,NAVB,neutral
883852.0,"Navidea Biopharmaceutical Q1 EPS $(0.04), Made $276.445K Sales",2018-05-08 17:01:00-04:00,NAVB,neutral
883853.0,Navidea Biopharma Reports Deal To Sublicense NAV4694 Global Development Rights,2018-04-16 07:11:00-04:00,NAVB,neutral
883854.0,"Navidea Biopharmaceuticals Reports Q4 EPS $(0.03)  vs $(0.02) In Prior Year Period, Sales $395K vs $1.03M In Prior Year Period",2018-03-08 16:29:00-05:00,NAVB,neutral
883855.0,"Navidea Biopharma 8-K Shows Co. Entered Settlement Deal With Sinotau; Both Cos. Agreed To Stipulate To The Voluntarily Dismissal Of All Claims, No Other Terms Disclosed",2018-02-23 10:10:00-05:00,NAVB,neutral
883856.0,"Navidea Biopharma Reports Q3 EPS $(0.01) vs. $0.00 In Same Qtr. Last Year, Sales $224K vs. $1.8M YoY",2017-11-07 17:32:00-05:00,NAVB,neutral
883857.0,Navidea Reports Launch Of LYMPHOSEEK In Europe,2017-06-12 11:06:00-04:00,NAVB,neutral
883858.0,UPDATE: Navidea Says Paid to Ricardo Gonzalez Total of ~$617.88K,2017-05-16 16:34:00-04:00,NAVB,neutral
883859.0,"8-K from Navidea Shows Co. Received Ruling In Favor of Ricardo Gonzalez, Finding He Was Terminated by Co. Without Cause",2017-05-16 16:33:00-04:00,NAVB,positive
883860.0,Navidea Biopharmaceuticals Reports Q1 EPS $0.52 vs $(0.02) In Prior Year Period,2017-05-09 16:42:00-04:00,NAVB,neutral
883861.0,"Navidea Reports Q4 EPS $(0.02) vs $(0.02) in Same Qtr. Last Year, Sales $3.4M",2017-03-29 16:11:00-04:00,NAVB,neutral
883862.0,Navidea Biopharma Files Non-Timely 10-K,2017-03-16 12:12:00-04:00,NAVB,neutral
883863.0,Navidea Shares Resume Trade,2017-02-23 10:30:00-05:00,NAVB,positive
883864.0,Navidea Biopharmaceuticals and Subsidiary Macrophage Therapeutics To Pay CRG $59M In Payments Of Amounts Owing Pursuant To Previous Loan Documents,2017-02-23 10:18:00-05:00,NAVB,negative
883865.0,Navidea 8-K Filing Just Out,2017-02-23 10:17:00-05:00,NAVB,neutral
883866.0,Navidea Shares Halted News Pending,2017-02-23 10:02:00-05:00,NAVB,positive
883867.0,12 Biggest Mid-Day Gainers For Friday,2016-11-25 12:07:00-05:00,NAVB,neutral
883868.0,Mid-Day Market Update: Crude Oil Down 3.5%; Navidea Shares Spike Higher,2016-11-25 12:06:00-05:00,NAVB,negative
883869.0,Mid-Morning Market Update: Markets Open Higher; Ctrip.Com To Acquire Skyscanner,2016-11-25 10:08:00-05:00,NAVB,neutral
883870.0,Navidea Biopharma +40% Premarket @$1.12; Co Announced Asset Purchase Agreement with Cardinal Health on Wednesday,2016-11-25 08:32:00-05:00,NAVB,positive
883871.0,"Navidea Biopharma Resumes Trading, Now Up 4.59%",2016-11-23 15:24:00-05:00,NAVB,neutral
883872.0,UPDATE: Navidea Will Receive $80M From Cardinal Health At Closing And Potential To Earn Up To $230M Based On Certain Milestones Through 2026,2016-11-23 15:16:00-05:00,NAVB,positive
883873.0,Navidea Signs Asset Purchase Agreement with Cardinal Health,2016-11-23 15:14:00-05:00,NAVB,positive
883874.0,Navidea Biopharmaceuticals Inc Shares Halted News Pending,2016-11-23 14:53:00-05:00,NAVB,positive
883875.0,"Navidea Reports Q3 EPS Breakeven vs. Est. $(0.02), Rev. $8.49M vs. Est. $6.47M",2016-11-03 07:00:00-04:00,NAVB,neutral
883876.0,"Navidea Names Michael Goldberg Pres, CEO; Eric Rowinsky Named Chair",2016-09-26 17:00:00-04:00,NAVB,neutral
883877.0,"Benzinga's M&A Chatter for Tuesday September 6, 2016",2016-09-06 19:33:00-04:00,NAVB,neutral
883878.0,Navidea Biopharmaceuticals to Hold Investor Update Call on Wednesday Sep 7 @8:30 AM ET,2016-09-06 15:22:00-04:00,NAVB,neutral
883879.0,Mid-Afternoon Market Update: Gold Futures Up 2%; CoLucid Shares Climb After Migraine Drug Achieves Primary And Key Secondary Endpoints,2016-09-06 14:33:00-04:00,NAVB,positive
883880.0,12 Biggest Mid-Day Gainers For Tuesday,2016-09-06 12:46:00-04:00,NAVB,neutral
883881.0,Mid-Day Market Update: Navistar Rises After Strategic Alliance With Volkswagen Truck & Bus; Tonix Shares Drop,2016-09-06 12:08:00-04:00,NAVB,neutral
883882.0,15 Stocks Moving In Tuesday's Pre-Market Session,2016-09-06 08:22:00-04:00,NAVB,neutral
883883.0,Navidea Biopharma +64.71% Premarket @$0.56; Co Announced LoI to Sell Lymphoseek in North America to Cardinal Health,2016-09-06 07:58:00-04:00,NAVB,neutral
883884.0,Navidea Biopharma Announces Letter of Intent to Sell Lymphoseek in North America to Cardinal Health for $80M and Up to $310M,2016-09-06 07:00:00-04:00,NAVB,neutral
883885.0,Navidea Biopharmaceuticals Files for Non-Timely 10-Q,2016-08-10 15:46:00-04:00,NAVB,neutral
883886.0,"Navidea Reports Q2 EPS $(0.04) vs. Est. $(0.03), Rev. $5.394M vs. Est. $5.24M",2016-08-04 08:02:00-04:00,NAVB,neutral
883887.0,Navidea Reports Received IRB Approval for Lymphoseek RA Protocol,2016-07-19 07:00:00-04:00,NAVB,positive
883888.0,"Navidea announces positive study results for Lymphoseek studies; positive comparative results versus commonly-used, non-receptor-targeted imaging agents",2016-06-16 16:17:00-04:00,NAVB,positive
883889.0,UPDATE: Navidea Reiterates Firmly Held Position Alleged Claims Do Not Constitute Events of Default Under Loan Deal,2016-06-02 17:13:00-04:00,NAVB,neutral
883890.0,8-K from Navidea Shows Co. Continues to Explore Financing Arrangements In Order to Refinance CRG Debt,2016-06-02 17:13:00-04:00,NAVB,negative
883891.0,Navidea Biopharma Awarded Fast-Track SBIR Grant Funds Of Potentially $1.8M To Be Released in 3 Parts Over 2.5 Years With Goal Of Completing IND Submission For Manocept Construct,2016-05-26 12:19:00-04:00,NAVB,positive
883892.0,Navidea Biopharma Reports Won $1.8M Fast-Track NIH SBIR Grant for Manocept's Evaluation in Kaposi's Sarcoma,2016-05-26 12:18:00-04:00,NAVB,positive
883893.0,UPDATE: Navidea Shares Halted with News Pending,2016-05-26 12:00:00-04:00,NAVB,positive
883894.0,Navidea Biopharma Shares Halted,2016-05-26 11:59:00-04:00,NAVB,positive
883895.0,12 Stocks Moving In Monday's Pre-Market Session,2016-05-23 08:26:00-04:00,NAVB,neutral
883896.0,Navidea Announces Unsolicited Offer to Refinance CRG Loan,2016-05-23 06:56:00-04:00,NAVB,neutral
883897.0,"Navidea Q1 EPS ($0.02) vs ($0.03) est, Revenue $4.7M vs $4.7M est",2016-05-17 07:04:00-04:00,NAVB,neutral
883898.0,Navidea Biopharmaceuticals Files Non-Timely 10@,2016-05-10 16:30:00-04:00,NAVB,neutral
883899.0,Navidea Names Jed Latkin as Interim Chief Operating Officer,2016-04-26 17:01:00-04:00,NAVB,neutral
883900.0,Here's Why Navidea Biopharmaceuticals Surged 25%,2016-04-15 16:10:00-04:00,NAVB,neutral
883901.0,"Navidea, Macrophage Offer Business Update",2016-04-15 07:01:00-04:00,NAVB,neutral
883902.0,8-K from Navidea Biopharma Shows Michael Goldberg Named Chair,2016-04-06 17:09:00-04:00,NAVB,neutral
883903.0,Navidea Offers Update on Clinical Development Plan for Diagnostic Use of Lymphoseek IV in RA,2016-04-04 07:01:00-04:00,NAVB,neutral
883904.0,Navidea Sees FY 2016 Revenue $23M to $25M vs $24.3M est,2016-03-23 06:34:00-04:00,NAVB,neutral
883906.0,"Earnings Scheduled For March 23, 2016",2016-03-23 04:16:00-04:00,NAVB,neutral
883907.0,Navidea Biopharmaceuticals Enrolls First Patient in Fast Track Granted Cervical Cancer Study of Lymphoseek®,2016-02-11 07:00:00-05:00,NAVB,negative
883908.0,Navidea Sees FY15 Lymphoseek Sales To Navidea Of $10.2M,2016-02-02 17:11:00-05:00,NAVB,neutral
883909.0,"UPDATE: Navidea '15 Commercial Highlights: Total Brand Sales ~$20M, Nearly Tripled Number of Accounts Which Averaged 20+ Doses/Month",2016-02-02 17:10:00-05:00,NAVB,positive
883910.0,"Navidea Issues Update on Lymphoseek, Immunodiagnostics Development Pipeline",2016-02-02 17:08:00-05:00,NAVB,neutral
883911.0,Lymphoseek® Technically Successful in Evaluation of Sentinel Lymph Node Biopsy in Patients Undergoing Neoadjuvant Chemotherapy,2015-12-10 16:32:00-05:00,NAVB,positive
883912.0,US Stock Futures Surge; All Eyes On Jobs Report,2015-12-04 07:11:00-05:00,NAVB,neutral
883913.0,Navidea Biopharmaceuticals Announces Positive Lymphoseek Results,2015-12-04 05:11:00-05:00,NAVB,positive
883914.0,Navidea Biopharmaceuticals Announces Dual Listing on Tel Aviv Stock Exchange,2015-09-02 07:32:00-04:00,NAVB,neutral
883915.0,Navidea Biopharma Announces Will Register Shares for Dual Listing on Tel-Aviv Exchange,2015-08-24 07:31:00-04:00,NAVB,positive
883916.0,Navidea Reports Publication of Lymphoseek Results: Showed Lymphoseek Minimized Patients Discomfort While Allowing For Effective SLN Mapping,2015-08-20 07:31:00-04:00,NAVB,positive
883917.0,"Navidea Biopharma Reports Q2 Loss $0.06 Vs Est Loss $0.04, Sales $2.87M vs Est $2.18M",2015-07-30 07:33:00-04:00,NAVB,negative
883918.0,Macrophage Therapeutics Reports Data Demonstrating a Manocept™ Drug Conjugate Induces Apoptosis in CD206 Positive Kaposi's Sarcoma and Tumor Associated Macrophages,2015-07-02 07:45:00-04:00,NAVB,positive
883919.0,Navidea Announces Clinical Data for Manocept Shows Agent Localizes in Multiple KS Lesions,2015-07-02 07:30:00-04:00,NAVB,neutral
883920.0,"BIND Therapeutics, Navidea's Macrophage Report Collab for Engineering CD206 Target Accurin Nanoparticle Using Manocept Macrophage Targeting Platform",2015-06-11 08:02:00-04:00,NAVB,neutral
883921.0,Navidea Announces Manocept Study Results in Rheumatoid Arthritis to be Presented at EULAR '15 ECR,2015-06-11 07:31:00-04:00,NAVB,neutral
883922.0,Navidea Reports Positive Lymphoseek Comparative Results in Injection Site Pain Study in Breast Cancer,2015-06-08 16:34:00-04:00,NAVB,negative
883923.0,"Navidea Reports Q1 Sales $2.1M vs $2.11M Est., Loss of $0.05/Share vs Loss of $0.03/Share Est.",2015-05-12 07:30:00-04:00,NAVB,negative
883924.0,"Navidea Secures $60M Loan With CRG to Support Lymphoseek Commercialization, Advancement of Development Pipeline",2015-05-11 16:32:00-04:00,NAVB,positive
883925.0,Navidea Biopharm Enters Agreement With Alseres to Terminate NAV5001 Sub-License Agreement,2015-04-27 07:32:00-04:00,NAVB,positive
883926.0,"Navidea Offers Data for Manocept CD206 Targeting Platform Shows Potential to Impact Tumor-Associated Macrophages, Kaposi's Sarcoma Tumor Cells",2015-04-22 08:16:00-04:00,NAVB,negative
883927.0,Morning Market Gainers,2015-03-05 09:41:00-05:00,NAVB,neutral
883928.0,Benzinga's Top #PreMarket Gainers,2015-03-05 08:13:00-05:00,NAVB,positive
883929.0,CORRECTION: Navidea Biopharm Reported Q3 Revenues Of $2.2B Vs Est $2.10,2015-03-05 07:36:00-05:00,NAVB,neutral
883930.0,"Navidea Biopharm Reports Q3 EPS -$0.08 Vs Est -$0.05, Sales $2.2M Vs Est $2.10",2015-03-05 07:32:00-05:00,NAVB,neutral
883931.0,"UPDATE Navidea May Receive Additional Milestone Payments Up to $5M, Royalties on Net Sales in Europe",2015-03-05 07:20:00-05:00,NAVB,neutral
883932.0,Navidea Awarded $2M Parnership With Norgine For Lymphoseek Partnership,2015-03-05 07:18:00-05:00,NAVB,positive
883933.0,Gilead's Sofosbuvir Just Made Achillion Investors Very Happy,2015-02-09 22:01:00-05:00,NAVB,positive
883934.0,UPDATE: Navidea Reports Prelim. FY14 Sales $6.3M vs $6.2M Est.,2015-02-09 07:33:00-05:00,NAVB,neutral
883935.0,Navidea Reports Prelim. Q4 Sales $2.2M vs $2.1M Est.,2015-02-09 07:32:00-05:00,NAVB,neutral
883936.0,Navidea's Macrophage Therapeutics Annouces Data Of Manocept Platform Compound Tilmanocept,2014-12-15 13:22:00-05:00,NAVB,neutral
883937.0,"Navidea Biopharma Shares Resume Trading, Now +6%",2014-12-15 13:19:00-05:00,NAVB,positive
883938.0,Data Presented by Independent Academic Collaborators Demonstrate Ability of Novel Manocept Immunotherapy to Kill Activated Macrophages from KS Patients,2014-12-15 13:17:00-05:00,NAVB,negative
883939.0,Navidea Biopharma Shares Indicated with Opening Delay Amid Code News Pending,2014-12-15 09:23:00-05:00,NAVB,neutral
883940.0,European Commission Approves Navidea's Sentinel Lymph Node Detection Agent Lymphoseek,2014-11-20 07:31:00-05:00,NAVB,positive
883941.0,"Navidea Biopharmaceuticals Director Goldberg Buys 100,000 Shares @$1.08/Share -Form 4",2014-11-17 16:37:00-05:00,NAVB,positive
883942.0,"Navidea Biopharmaceuticals Director Ford Buys 10,000 Shares @$1.03 -Form 4",2014-11-12 11:37:00-05:00,NAVB,positive
883943.0,Navidea Receives $1.1M PDUFA Filing Fee Refund For Award Of Orphan Drug Status; Platinum Partners Reaffirms Commitment To Line Of Credit,2014-11-11 07:30:00-05:00,NAVB,positive
883944.0,Navidea Announces Rick Gonzalez As New CEO,2014-10-15 08:02:00-04:00,NAVB,neutral
883945.0,FDA Approves Expanded Navidea's Lymphoseek for Lymphatic Mapping in Solid Tumors ,2014-10-15 07:04:00-04:00,NAVB,positive
883946.0,Navidea Reports CHMP Recommended European Approval for Lymphoseek,2014-09-26 07:27:00-04:00,NAVB,positive
883947.0,Navidea Awarded $1.6M Grant,2014-09-23 07:31:00-04:00,NAVB,positive
883948.0,Navidea Receives Orphan Drug Designation From FDA For Use Of Lymphoseek(R) In Head And Neck Cancers,2014-09-18 16:07:00-04:00,NAVB,neutral
883949.0,Agilis Biotherapeutics Names Dr. Mark Pykett AS CEO ,2014-09-10 13:00:00-04:00,NAVB,neutral
883950.0,"Navidea Biopharmaceuticals, Inc. Reports Q2 EPS of $(0.07), Inline",2014-08-06 07:32:00-04:00,NAVB,neutral
883951.0,"Navidea Joins Essex Woodland's Rheumco, Will Develop Radiopharmaceuticals To Detect And Treat Arthritic Diseases",2014-07-16 07:32:00-04:00,NAVB,positive
883952.0,"From Navidea 8K: Changest R&D Expance To Less Than $20M For 2014, From $25-50M",2014-06-16 15:59:00-04:00,NAVB,neutral
883953.0,"FDA Has Approved Navidea's Lymphoseek for Helping Determine Extent of Head, Neck Cancer in Body",2014-06-13 10:32:00-04:00,NAVB,negative
883954.0,"Navidea Reports Results from Post-Hoc Analysis of Phase 3 Clinical Trial of NEO3-06, Shows Preferential Accumulation in Tumor-Positive Sentinel Lymph Nodes",2014-06-11 07:32:00-04:00,NAVB,neutral
883955.0,UPDATE: Navidea Biopharma Announces Positive Lymphoseek Injection Results,2014-06-10 16:34:00-04:00,NAVB,positive
883956.0,Navidea Biopharma Announces Positive Lymphoseek Injection Results,2014-06-10 16:31:00-04:00,NAVB,positive
883957.0,UPDATE: JMP Securities Reiterates On Navidea Biopharmaceuticals On Pipeline Restructuring,2014-05-19 08:19:00-04:00,NAVB,positive
883958.0,Navidea Announces Restructuring of Pipeline Development; Michael Goldberg Appointed Interim CEO,2014-05-15 16:33:00-04:00,NAVB,neutral
883959.0,Navidea Biopharma Files $100M Mixed Securities Shelf,2014-05-08 17:13:00-04:00,NAVB,positive
883960.0,"Navidea Biopharmaceuticals, Inc. Reports Q1 EPS of $(0.08) vs $(0.10) Est",2014-05-07 07:32:00-04:00,NAVB,neutral
883961.0,"Navidea Biopharmaceuticals, Inc. Reports Q1 EPS of $(0.08) vs $(0.10) Est",2014-05-07 07:31:00-04:00,NAVB,neutral
883962.0,Navidea Provides Updates on Lymphoseek Programs ,2014-04-17 17:33:00-04:00,NAVB,neutral
883963.0,Navidea Announces Presentation of Study Findings of Manocept Platform Imaging Agent in Kaposi Sarcoma at AACR Annual Meeting,2014-04-10 07:31:00-04:00,NAVB,neutral
883964.0,"UPDATE: Navidea Believes Course of Review Continues to be Supportive of Market Development Plans, Outlook for Revenue Generation In Europe Beginning In 2015",2014-03-19 17:33:00-04:00,NAVB,positive
883965.0,"UPDATE: Navidea Biopharma Offers Update on EMA Application For Lymphoseek, Sets Second sNDA PDUFA Target Date Oct. 16th",2014-03-19 17:33:00-04:00,NAVB,neutral
883966.0,Navidea Biopharmaceuticals Provides Update on EMA Application For Lymphoseek,2014-03-19 17:31:00-04:00,NAVB,neutral
883967.0,"Navidea Biopharma Announces Presentation of Lymphoseek Three-Year Recurrence, Survival Outcomes, Says Disease-Specific Survival Rate 98.6%",2014-03-14 07:37:00-04:00,NAVB,neutral
883968.0,"Morning Gainers for Mar. 6, 2014: PXLW, SGMO, ERII, RGSE, NAVB, PSTI",2014-03-06 11:08:00-05:00,NAVB,neutral
883969.0,"Navidea BioPharma Closes $30M Loan with Oxford Finance, Issued Warrants for 391K Shares at $1.92/Share, Will Use Proceeds for Lymposeek Commercialization",2014-03-06 07:08:00-05:00,NAVB,positive
883970.0,"Morning Movers for Mar. 5, 2014: FCEL, ARWR, SWHC, CPST Moving Higher",2014-03-05 09:52:00-05:00,NAVB,neutral
883971.0,"Navidea Announces FDA Sets Target Review Date for Lymphoseek sNDA of June 16, 2014",2014-02-18 07:35:00-05:00,NAVB,neutral
883972.0,Form S-3 from Navidea Biopharma Shows Registration for Up to 100K Shares for Selling Holders,2014-01-13 15:17:00-05:00,NAVB,positive
883973.0,Navidea Biopharma Expands Lymphoseek Global Distribution Pact to Taiwan,2014-01-07 07:31:00-05:00,NAVB,positive
883974.0,Navidea Announces EMA Continues Marketing Authorization Application Review for Lymphoseek,2013-12-19 19:34:00-05:00,NAVB,neutral
883975.0,"Navidea Biopharma Submits sNDA for Lymphoseek for Sentinel Lymph Node Detection in Patients with Head, Neck Cancer",2013-12-17 09:20:00-05:00,NAVB,negative
883976.0,"Navidea Announces FDA Fast Track Designation for Lymphoseek for Sentinel Lymph Node Detection in Patients with Head, Neck Cancer",2013-12-10 07:32:00-05:00,NAVB,negative
883977.0,"Option Alert: Navidea Biopharmaceuticals January $3 Call; 10,231 Contracts Traded Friday vs 22,242 Open Interest; Currently $1.61",2013-11-29 12:59:00-05:00,NAVB,positive
883978.0,Navidea Biopharma Reports Collaboration with University of Alabama-Birmingham on Clinical Study Evaluating RIGS Agent,2013-11-26 07:31:00-05:00,NAVB,neutral
883979.0,Navidea Biopharmaceuticals Awarded New US Patent for NAV5001 ,2013-11-14 08:36:00-05:00,NAVB,positive
883980.0,UPDATE: Aegis Capital Reiterates on Navidea Biopharmaceuticals Following 3Q 2013 Earnings Report,2013-11-13 10:45:00-05:00,NAVB,neutral
883981.0,Navidea Will Collaborate with University of California - San Francisco on Clinical Study Evaluating Manocept Platform,2013-11-13 07:33:00-05:00,NAVB,neutral
883982.0,Navidea Biopharmaceuticals Rises 6.5%; May be Attributed to Seeking Alpha Post,2013-11-11 09:31:00-05:00,NAVB,neutral
883983.0,Stocks Hitting 52-Week Lows,2013-10-29 11:23:00-04:00,NAVB,negative
883984.0,"Navidea Biopharma Files Prospectus for 10.6M Shares, Warrants Up to 3.2M",2013-09-24 09:26:00-04:00,NAVB,positive
883985.0,"Navidea Says Lymphoseek Met Primary Endpoint in NEO3-06 Trial, Looking to File sNDA by Year End",2013-09-19 16:29:00-04:00,NAVB,neutral
883986.0,"Navidea Biopharma, Osobio Report Manufacturing Services Pact in Form 8-K",2013-09-12 16:05:00-04:00,NAVB,neutral
883987.0,US Stock Futures Up Ahead Of Jobless Claims,2013-08-22 07:21:00-04:00,NAVB,neutral
883988.0,Navidea Biopharmaceuticals Announces Agreement with FDA on Special Protocol Assessments for NAV5001 Phase 3 Program ,2013-08-22 07:01:00-04:00,NAVB,positive
883989.0,"Navidea Biopharmaceuticals, Inc. Reports Q2 EPS of $(0.09) vs $(0.06) Est; Revenue of $195.28K vs $530.0K Est",2013-08-07 07:36:00-04:00,NAVB,neutral
883990.0,Navidea Biopharmaceuticals Highlights New Data for NAV4694 PET β-Amyloid Imaging Agent Presented at AAIC 2013 ,2013-07-22 09:01:00-04:00,NAVB,neutral
883991.0,Navidea Biopharmaceuticals' NAV4694 β-Amyloid Imaging Agent to Be Used in Alzheimer's Disease Studies by Australian Imaging,2013-07-16 09:32:00-04:00,NAVB,neutral
883992.0,Navidea Biopharmaceuticals Announces Board Member Resignation ,2013-07-15 16:35:00-04:00,NAVB,negative
883993.0,"Navidea Biopharmaceuticals Closes $25M Debt Financing with GE Capital, Healthcare Financial Services ",2013-06-26 08:03:00-04:00,NAVB,negative
883994.0,Navidea Biopharmaceuticals Announces Results from Lymphoseek® Study on Accuracy of Lymph Node Detection from Injection Time to Surgery; Working with FDA on Evaluating SNDA Submission,2013-06-12 09:04:00-04:00,NAVB,neutral
883995.0,Navidea Biopharmaceuticals Announces Results from Lymphoseek(R) Study on Accuracy of Lymph Node Detection from Injection Time to Surgery,2013-06-11 09:02:00-04:00,NAVB,neutral
883996.0,"Navidea Says Lymphoseek Results Statistically Significant, Results Unveiled at SNMMI",2013-06-10 16:19:00-04:00,NAVB,positive
883997.0,Navidea Announces Data Presentations at 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) ,2013-06-04 09:02:00-04:00,NAVB,neutral
883998.0,Navidea Biopharma Issues Highlights of Lymphoseek Data at JIOC,2013-05-29 09:23:00-04:00,NAVB,neutral
883999.0,"Navidea Biopharma Announces Manufacturing, Supply Deal with Nordion",2013-05-15 16:39:00-04:00,NAVB,neutral
884000.0,"Navidea Biopharmaceuticals, Inc. Reports Q1 EPS of $(0.06) vs $(0.07) Est",2013-05-08 07:03:00-04:00,NAVB,neutral
884001.0,Navidea Announces Launch of Lymphoseek in US,2013-05-01 07:43:00-04:00,NAVB,neutral
884002.0,Navidea Biopharma Reports Underwritten Sale of Common Stock,2013-04-24 08:45:00-04:00,NAVB,neutral
884003.0,"Janney Capital Initiates Coverage on Navidea Biopharmaceuticals, Inc. at Buy, Announces $5.00 PT",2013-04-09 16:40:00-04:00,NAVB,neutral
884004.0,"Mid-Day Market Update: Markets Heading Upwards, MGIC Investment Drops",2013-04-09 13:08:00-04:00,NAVB,neutral
884005.0,Navidea Biopharma Reports Top-Line Results from Interim Analysis of Lymphoseek Phase 3 Trial,2013-04-04 08:01:00-04:00,NAVB,neutral
884006.0,Navidea Biopharmaceuticals Announces Enrollment of First Subject in Phase 2b Trial of NAV4694 in Subjects with Mild Cognitive Impairment (MCI) ,2013-03-27 09:01:00-04:00,NAVB,neutral
884007.0,13 Drugs Pending FDA Approval in 2013,2013-03-26 13:19:00-04:00,NAVB,positive
884008.0,Results of Lymphoseek Phase 3 Clinical Trials in Breast Cancer Published in Annals of Surgical Oncology ,2013-03-21 09:02:00-04:00,NAVB,negative
884009.0,Navidea BioPharma Will Hold Call to Discuss Lymphoseek FDA Approval at 4PM EST Today,2013-03-13 14:48:00-04:00,NAVB,positive
884010.0,"Navidea BioPharma Shares Now Sinking Following Initial  Knee-Jerk Higher, Stock Now Down 10%",2013-03-13 11:20:00-04:00,NAVB,positive
884011.0,Navidea Biopharmaceuticals Spikes Higher on FDA Approval of Lymphoseek,2013-03-13 11:16:00-04:00,NAVB,positive
884012.0,FDA Approves Navidea BioPharma's Lymphoseek,2013-03-13 11:16:00-04:00,NAVB,positive
884013.0,"Navidea Biopharmaceuticals, Inc. Reports Q4 EPS of $(0.07) vs $(0.08) Est",2013-03-06 16:25:00-05:00,NAVB,neutral
884014.0,UPDATE: Piper Jaffray Initiates Navidea Biopharmaceuticals with Underweight Rating on Innovative Pipeline,2013-03-06 08:49:00-05:00,NAVB,positive
884015.0,"Piper Jaffray Initiates Coverage on Navidea Biopharmaceuticals, Inc. at Underweight, Announces $1.50 PT",2013-03-05 16:09:00-05:00,NAVB,neutral
884016.0,Navidea to Collaborate with Maimonides Medical Center on Trial Utilizing Lymphoseek for Lymphatic Mapping in Colorectal Cancer,2013-02-04 09:30:00-05:00,NAVB,negative
884017.0,"Navidea Biopharma Sold 1,542,389 Shares at $3.10/Share",2013-01-30 09:14:00-05:00,NAVB,positive
884018.0,UPDATE: Aegis Capital Initiates Navidea Biopharmaceuticals at Hold ,2013-01-22 10:09:00-05:00,NAVB,neutral
884019.0,"Aegis Capital Initiates Coverage on Navidea Biopharmaceuticals, Inc. at Hold, Announces $3.00 PT",2013-01-22 08:54:00-05:00,NAVB,neutral
884020.0,"Burrill Initiates Coverage on Navidea Biopharmaceuticals, Inc. at Outperform, Announces $5.00 PT",2013-01-22 08:54:00-05:00,NAVB,neutral
884021.0,"Navidea Biopharma Offers Interim Analysis Point of Phase 3 Head, Neck Cancer Study of Lymphoseek",2013-01-03 09:05:00-05:00,NAVB,negative
884022.0,Navidea Submits Lymphoseek Marketing Application in Europe,2012-12-18 09:32:00-05:00,NAVB,neutral
884023.0,"Navidea to Present Data from Lymphoseek Studies at RSNA, CTRC-AACR Meetings",2012-11-26 10:23:00-05:00,NAVB,neutral
884024.0,"Navidea Biopharma Says PDUFA Goal Date for Lymphoseek April 30, 2013",2012-11-13 16:31:00-05:00,NAVB,neutral
884025.0,Navidea Biopharmaceuticals Announces the Presentation of Lymphoseek Data at Upcoming Scientific Meetings in October,2012-10-10 14:23:00-04:00,NAVB,neutral
884026.0,Morning Market Losers,2012-09-11 09:55:00-04:00,NAVB,negative
884027.0,Benzinga's Top Pre-Market Losers,2012-09-11 08:23:00-04:00,NAVB,negative
884028.0,Navidea Biopharamaceuticals Falls 35% After-Hours on FDA Complete Response Letter,2012-09-10 16:37:00-04:00,NAVB,neutral
884029.0,Navidea Biopharmaceuticals Receives Complete Response Letter from FDA for Lymphoseek,2012-09-10 16:04:00-04:00,NAVB,neutral
884030.0,Navidea Pharma Receives FDA Response Letter Due to Lymphoseek Manufacturing Deficiencies ,2012-09-10 16:04:00-04:00,NAVB,neutral
884031.0,UPDATE: Navidea Biopharmaceuticals off Lows Following Bear Raid,2012-09-10 15:37:00-04:00,NAVB,negative
884032.0,Navidea Biopharamaceuticals Spikes Lower,2012-09-10 15:23:00-04:00,NAVB,negative
884033.0,Navidea Biopharmaceuticals Completes License for Parkinson's Disease Imaging Agent   ,2012-07-31 16:32:00-04:00,NAVB,neutral
884035.0,Head-to-Head Study Comparing Navidea's AZD4694 to the Gold Standard for Imaging Beta Amyloid Protein Deposits Presented at Alzheimer's Association International Conference  ,2012-07-23 08:04:00-04:00,NAVB,neutral
884036.0,Biotechs With Upcoming PDUFA Dates,2012-07-18 15:09:00-04:00,NAVB,neutral
884037.0,Navidea Biopharmaceuticals Elects to Extend Evaluation Period for Option to License Parkinson's Disease Imaging Agent   ,2012-06-26 16:00:00-04:00,NAVB,positive
884038.0,Meta-analysis of Navidea Biopharmaceuticals Lymphoseek® Phase 3 Data Compared to Standard of Care Techniques Published in Conjunction with the ASCO Annual Meeting   ,2012-06-04 15:47:00-04:00,NAVB,positive
884039.0,Presentation Highlights Clinical Potential of Navidea Biopharmaceuticals' β-Amyloid Imaging Biomarker AZD4694   ,2012-05-29 09:02:00-04:00,NAVB,neutral
884040.0,Navidea: FDA Extends PDUFA Date for Lymphoseek by Three Months   ,2012-04-03 09:01:00-04:00,NAVB,positive
884041.0,Navidea Biopharmaceuticals Announces Presentation of Lymphoseek® Phase 3 Data at Society of Surgical Oncology Meeting   ,2012-03-28 07:01:00-04:00,NAVB,neutral
884042.0,"Option Alert: Navidea Biopharmaceuticals January 2013 5 Call; Block Trade, 4,900 Contracts",2012-02-08 12:54:00-05:00,NAVB,negative
884043.0,"Rodman & Renshaw Reiterates Outperform, $7 Target on Navidea Biopharmaceuticals",2012-02-06 10:24:00-05:00,NAVB,neutral
884044.0,Navidea Obtains Positive EMA Guidance for Lymphoseek; Company to Submit Marketing Authorization Application in Europe  ,2012-02-01 16:02:00-05:00,NAVB,positive
884045.0,LifeTech Capital Maintains Strong Speculative Buy on Navidea After Alseres Agreement,2012-01-26 09:25:00-05:00,NAVB,positive
884046.0,Navidea Biopharmaceuticals Enters into Option Agreement to License Parkinson's Disease Imaging Agent  ,2012-01-25 16:03:00-05:00,NAVB,positive
884047.0,"Option Alert: Navidea Biopharmaceuticals January 2013 3 Call; Block Trade, 4,939 Contracts",2012-01-20 13:28:00-05:00,NAVB,negative
